Feb 09, 2023 / 03:10PM GMT
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
All right. Thanks, everybody. I'm Seamus Fernandez, the global biopharma analyst here at Guggenheim Securities. This is our Fifth Annual Oncology Conference.
Really pleased to be joined by Eli Lilly. To my far left is Jake Van Naarden, CEO of Loxo Oncology at Lilly and President, Lilly Oncology; and Dr. David Hyman, immediately to my left here, is Chief Medical Officer of Lilly Oncology.
Questions and Answers:
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global PharmaceuticalsSo Jake, maybe just to kick us off, you can give us a little bit of a sense of key drivers. I think we were just talking about how impressive a quarter we just saw out of Verzenio, but maybe I'll leave it for you to take it away from there.
Jacob S. Van Naarden - Eli Lilly and Company - Senior VP, CEO of Loxo Oncology & President of Lilly Oncology
Yes,